Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies

Next Previous
Trial Profile

A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACTR707 (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Cogent Biosciences

Most Recent Events

  • 02 Mar 2020 Status changed from recruiting to discontinued, according to an Unum Therapeutics media release.
  • 04 Nov 2019 According to an Unum Therapeutics media release, fives clinical sites are active in this study. The company expects to report preliminary data from this study from first cohort patients by the end of this year and expects data from the multiple dose cohort in 2020.
  • 28 Mar 2019 According to an Unum Therapeutics media release, compnay plans to report initial clinical data from the ongoing dose escalation at the end of 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top